Evidence map›Paper›PMID 29969536›Full record

ArticleESC heart failure2018

Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure.

Julio A Chirinos, Mayank Sardana, Garrett Oldland, Bilal Ansari, Jonathan Lee, Anila Hussain, Anique Mustafa, Scott R Akers, Wen Wei, Edward G Lakatta and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes.International journal of molecular sciences · 2025
    Review
  4. Article
  5. New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Julio A ChirinosCorporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.
Mayank SardanaUniversity of Massachusetts Medical School, Worcester, MA, USA.
Garrett OldlandCorporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.
Bilal AnsariHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Jonathan LeeUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Anila HussainHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Anique MustafaHospital of the University of Pennsylvania, Philadelphia, PA, USA.
Scott R AkersCorporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.
Wen WeiNational Institute of Aging, Baltimore, MD, USA.
Edward G LakattaNational Institute of Aging, Baltimore, MD, USA.
Olga V FedorovaNational Institute of Aging, Baltimore, MD, USA.
Hospital of the University of Pennsylvania · USPhiladelphia VA Medical Center · USNational Institute on Aging · USInstitute of Aging · CAUniversity of Massachusetts Chan Medical School · USUniversity of Pennsylvania · US

Funding

Sodium pump ligands in blood pressure regulation and profibrotic signaling in hypertension, chronic kidney disease and aging in males and femalesZIAAG000609 · NIA · NATIONAL INSTITUTE ON AGING · PI FEDOROVA, OLGA V · 2009 to 2025
$17.3M
NIA NIH HHSNIH HHS 5-R21-AG-043802-02NIH HHS R01 HL 121510-01A1NIH HHS R56HL-124073-01A1VA
6 · The paper itself

Abstract

aimsThe arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown. METHODS AND

resultsWe studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09-0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = -0.23; 95% CI = -0.42 to -0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09-0.43; P = 0.003) and with an increased risk of death or HF admissions during follow-up (hazard ratio = 1.61; 95% CI = 1.13-2.29; P = 0.008).

conclusionsArginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess.

Indexed as

AgedArginine VasopressinAtrial Natriuretic FactorBiomarkersDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHeart FailureHeart VentriclesHumansHypertrophy, Left VentricularMagnetic Resonance Imaging, CineMaleMiddle AgedPrognosisArginine VasopressinAtrial Natriuretic FactorBiomarkersArginine vasopressinAtrial natriuretic peptideHeart failure with preserved ejection fractionLeft atriumLeft ventricular hypertrophy

Identifiers

PMID29969536
PMCPMC6165935
OpenAlexW2811122665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.